GlaxoSmithKline plans to eliminate as many as 850 jobs in R&D in the U.S. and Britain, which represents 6% of the company’s total R&D staff. According to a company statement, the cuts were necessary “to ensure that we can invest in key areas of future growth and evolve our business to compete effectively in what is a rapidly changing and challenging environment for pharmaceutical companies.”     Earlier this year, the company had announced plans to cut 350 R&D po...